
Advanced Statistics in Regulatory Critical Clinical Initiatives
Chapman & Hall/CRC (Publisher)
1st Edition
Published on 27. May 2024
Book
Paperback/Softback
307 pages
978-0-367-60995-5 (ISBN)
Description
Advanced Statistics in Regulatory Critical Clinical Initiatives is focused on the critical clinical initiatives introduced by the 21st Century Cure Act passed by the United States Congress in December 2016. The book covers everything from the outline of the initiatives to analysis on the effect on biopharmaceutical research and development. Advanced Statistics in Regulatory Critical Clinical Initiatives provides innovative ways to resolve common challenges in statistical research of rare diseases such small sample sizes and provides guidance for combined use of data. With analysis from regulatory and scientific perspectives this book is an ideal companion for researchers in biostatistics, pharmaceutical development, and policy makers in related fields.
Key Features:
Provides better understanding of innovative design and analysis of each critical clinical initiatives which may be used in regulatory review/approval of drug development.
Makes recommendations to evaluate submissions accurately and reliably.
Proposes innovative study designs and statistical methods for oncology and/or rare disease drug development.
Provides insight regarding current regulatory guidance on drug development such as gene therapy and rare diseases.
Key Features:
Provides better understanding of innovative design and analysis of each critical clinical initiatives which may be used in regulatory review/approval of drug development.
Makes recommendations to evaluate submissions accurately and reliably.
Proposes innovative study designs and statistical methods for oncology and/or rare disease drug development.
Provides insight regarding current regulatory guidance on drug development such as gene therapy and rare diseases.
Reviews / Votes
"This is a must have book for any statistician working in the pharmaceutical industry that wants to have an introductory overview of the most recent and challenging issues and ongoing discussions in the field of statistical regulatory science."David Manteigas, Cmed Clinical Services, Portugal, ISCB, February 2023
More details
Series
Language
English
Place of publication
Boca Raton
United Kingdom
Publishing group
Taylor & Francis Ltd
Illustrations
30 s/w Zeichnungen, 21 s/w Tabellen, 30 s/w Abbildungen
21 Tables, black and white; 30 Line drawings, black and white; 30 Illustrations, black and white
Dimensions
Height: 254 mm
Width: 178 mm
Thickness: 17 mm
Weight
601 gr
ISBN-13
978-0-367-60995-5 (9780367609955)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions

Wei Zhang | Fangrong Yan | Feng Chen
Advanced Statistics in Regulatory Critical Clinical Initiatives
Book
05/2022
1st Edition
Chapman & Hall/CRC
€229.50
Shipment within 15-20 days

Wei Zhang | Fangrong Yan | Feng Chen
Advanced Statistics in Regulatory Critical Clinical Initiatives
E-Book
05/2022
1st Edition
Chapman & Hall/CRC
€73.99
Available for download

Wei Zhang | Fangrong Yan | Feng Chen
Advanced Statistics in Regulatory Critical Clinical Initiatives
E-Book
05/2022
1st Edition
Chapman & Hall/CRC
€73.99
Available for download
Persons
Wei Zhang is the Vice President, Head of Biometrics at AffaMed Therapeutics, New York.
Fangrong Yan is a Professor of Biostatistics in the School of Science, and Director of Biostatistics and Computational Pharmacy Research Center at China Pharmaceutical University (CPU).
Feng Chen is a Professor of Biostatistics in School of Public Health, Nanjing Medical University (NJMU).
Shein-Chung Chow is currently a Professor at the Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham.
Fangrong Yan is a Professor of Biostatistics in the School of Science, and Director of Biostatistics and Computational Pharmacy Research Center at China Pharmaceutical University (CPU).
Feng Chen is a Professor of Biostatistics in School of Public Health, Nanjing Medical University (NJMU).
Shein-Chung Chow is currently a Professor at the Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham.
Editor
Sen. Director & Head of US site, Clin. Dvlpmt & Reg, PPC
China Pharma Univ, China
Nanjing Med Univ, China
Duke Univ, USA
Content
1 Introduction, 2 Complex Innovative Design, 3 Validation Strategy for Biomarker guided Precision/Personalized Medicine, 4 Model-Informed Drug Development, 5 Real-world data and real-world evidence, 6 AI/ML in Medical Research and Drug Development, 7 Challenges in Cancer Clinical Trials, 8 Statistical Methods for Assessment of Biosimilars, 9 Statistical Methods for Assessment of Complex Generic Drugs, 10 Rare Diseases Drug Development